Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Intellectual Property Legal Issues Regulation

Medtech Connect Episode 12: Apple’s Patent Infringement Cases

  • Interviews

Executive Summary

Medtech Insight regulatory reporter Hannah Daniel speaks to Sanjay Voleti, AliveCor’s chief business officer, about his company’s patent infringement case against Apple and what it’s like to take on a tech giant over intellectual property.

 

Further Reading

‘More Than AI’ – AliveCor Tailors ECG Technology To Modern Care Demands

Apple Vs. AliveCor: ECG Patent Battle Headed To Import Ban Decision

ITC Ruling Hands AliveCor Big Win Against Tech Giant

Apple Drops Pulse Oximeter Features To Subvert Import Ban

Further Listening

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Table

View full table

Topics

Tags:
Intellectual Property Legal Issues Regulation
Latest Headlines

Warning Letters And Close-Outs – April 2024

To Be (a device) Or Not To Be. That’s The Legal Question

US FDA Grants Teal Health’s At-Home Cervical Screening Device Breakthrough Device Designation

Netherlands Pilots New Scientific Advice Service For Clinical Trials

See All
UsernamePublicRestriction

Register

MT154370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By